4
Changes in Ownership
Contineum Therapeutics, Inc. Filed Acc 0001628280-26-046654
CMO & Head of Development sold 10,833 shares at $16.02 ($173,590)
- CMO & Head of Development acquired 10,833 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Watkins Tim CMO & Head of Development | 2026-06-30 | Option exercise 10b5-1 | +10,833 | $4.50 | $48,749 | 19,794 | D: show line 1 in the form |
| Watkins Tim CMO & Head of Development | 2026-06-30 | Sale 10b5-1 | −10,833 | $16.02 | $173,590 | 8,961 | D: show line 2 in the form |
| Open-market sales · 10,833 sh · avg $16.02 · $173,590 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Watkins Tim CMO & Head of Development | 2026-06-30 | Option exercise · Stock Option (right to buy) 10b5-1 | −10,833 | 238,334 | D: show line 3 in the form |
Loading xslF345X06/wk-form4_1782947093.xml…